Ahmet Bertug Celik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmet Bertug Celik has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Tugce Colluoglu
Department of Cardiology, Faculty of Medicine, Dokuz Eylül University, 35340 İzmir, Türkiye
2 shared publications - Tuğba Kapanşahin
Karabük University, Faculty of Medicine, Department of Cardiology, Karabük, Türkiye
2 shared publications - Yesim Akin
Department of Cardiology, Karabük University Faculty of Medicine, Karabük, Türkiye
2 shared publications - Alper Bozkurt
Karabük University, Faculty of Medicine, Department of Cardiology, Karabük, Türkiye
1 shared publication - Bora Çekmen
Department of Emergency Medicine, Faculty of Medicine, Karabuk University, Karabuk, Turkiye
1 shared publication - Burak Oksuzoglu
Karabük University, Faculty of Medicine, Department of Cardiology, Karabük, Türkiye
1 shared publication
Latest Publications
- 4 May 2026
- Published by Elsevier in Heart & Lung
- Vol. 79, 102825
Prognostic power of electrical risk score in acute pulmonary embolism: insights beyond conventional risk stratification
- 4 May 2026
- Published by Elsevier in Heart & Lung
- Vol. 79, 102825
Prognostic power of electrical risk score in acute pulmonary embolism: insights beyond conventional risk stratification
- Open Access
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Loop Diuretics and Mortality in Heart Failure: A Propensity Score–Matched Study
Background: While loop diuretics remain a cornerstone of heart failure (HF) management, evidence directly comparing the clinical outcomes of torasemide and furosemide is still not clear. Objectives: We aimed to assess the comparison of mortality between furosemide and torasemide in patients with HF. Methods: This single‐center, retrospective, and observational cohort study included 627 patients with HF who were regularly prescribed furosemide or torasemide and were admitted to the emergency department or cardiology outpatient clinic between January 1, 2022, and June 30, 2023. Patients were divided into the two groups as follows: the furosemide group and the torasemide group. The primary outcome was defined as 1‐year all‐cause mortality. The primary outcome was assessed by Kaplan−Meier analyses in the whole study population and the 1:1 propensity score−matched cohort. Results: Of 627 eligible patients with HF, 497 were treated with furosemide, while 130 received torasemide. After propensity score matching analysis, 82 patients with HF in the furosemide group were compared with 82 patients with HF in the torasemide group. In the furosemide group, 1‐year all‐cause mortality was observed in 15 (18.3%) patients with HF, compared to 13 (15.9%) patients with HF in the torasemide group ( p : 0.678). Kaplan−Meier analysis showed that cumulative survival rates were comparable between the HF patients treated with furosemide and those treated with torasemide (log‐rank p : 0.661). Conclusions: In patients with HF, treatment with torasemide was associated with similar 1‐year all‐cause mortality compared to furosemide, underscoring the absence of a detectable prognostic difference between the two loop diuretic strategies.
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Open AccessLoop Diuretics and Mortality in Heart Failure: A Propensity Score–Matched Study
Background: While loop diuretics remain a cornerstone of heart failure (HF) management, evidence directly comparing the clinical outcomes of torasemide and furosemide is still not clear. Objectives: We aimed to assess the comparison of mortality between furosemide and torasemide in patients with HF. Methods: This single‐center, retrospective, and observational cohort study included 627 patients with HF who were regularly prescribed furosemide or torasemide and were admitted to the emergency department or cardiology outpatient clinic between January 1, 2022, and June 30, 2023. Patients were divided into the two groups as follows: the furosemide group and the torasemide group. The primary outcome was defined as 1‐year all‐cause mortality. The primary outcome was assessed by Kaplan−Meier analyses in the whole study population and the 1:1 propensity score−matched cohort. Results: Of 627 eligible patients with HF, 497 were treated with furosemide, while 130 received torasemide. After propensity score matching analysis, 82 patients with HF in the furosemide group were compared with 82 patients with HF in the torasemide group. In the furosemide group, 1‐year all‐cause mortality was observed in 15 (18.3%) patients with HF, compared to 13 (15.9%) patients with HF in the torasemide group ( p : 0.678). Kaplan−Meier analysis showed that cumulative survival rates were comparable between the HF patients treated with furosemide and those treated with torasemide (log‐rank p : 0.661). Conclusions: In patients with HF, treatment with torasemide was associated with similar 1‐year all‐cause mortality compared to furosemide, underscoring the absence of a detectable prognostic difference between the two loop diuretic strategies.